
For certain women with early stage breast cancer, a newer drug that combines an antibody with chemotherapy may cut the risk of disease recurrence in half, a new trial finds. The study focused on nearly 1,500 women with early stage breast cancer that was HER2-positive — meaning it carries a protein that promotes cancer growth.… read on >